显示样式:     当前分类: 医药    当前期刊: JAMA Psychiatry    加入关注    导出
我的关注
我的收藏
您暂时未登录!
登录
  • Corollary Discharge, Self-agency, and the Neurodevelopment of the Psychotic Mind
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-20
    Michele Poletti, Eva Gebhardt, Andrea Raballo
    更新日期:2017-09-20
  • Personality Change in the Preclinical Phase of Alzheimer Disease
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-20
    Antonio Terracciano, Yang An, Angelina R. Sutin, Madhav Thambisetty, Susan M. Resnick
    更新日期:2017-09-20
  • Factors to Consider for Reducing US Opioid-Related Deaths: Looking Beyond Access
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-13
    Nitigna Desai, Shane W. Kraus, Joseph R. Houchins

    To the Editor We want to thank Martins et al1 for their direction as we attempt to navigate and remap the current opioid epidemic’s vexing domestic landscape. As Martins et al1 reported, there was a 5-fold increase in heroin use and 3-fold increase in heroin use disorders from 2001 to 2013, which have likely contributed to the rise of US opioid-related deaths (ORDs) since 2002.2 One of the primary responses to the opioid crisis was increasing access to opioid-dependency medications, including buprenorphine, by increasing the number of prescribers.3 To explore the effectiveness of this intervention on ORDs in Massachusetts, we examined the number of buprenorphine prescribers and ORDs from 2010 to 2016.

    更新日期:2017-09-13
  • Factors to Consider for Reducing US Opioid-Related Deaths: Looking Beyond Access—ReplyFactors to Consider for Reducing US Opioid-Related Deaths—Reply
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-13
    Silvia S. Martins, Julian Santaella-Tenorio, Deborah S. Hasin

    In Reply We thank Desai et al for commenting on our article1 reporting trends in heroin use and heroin use disorder in the United States and for noting their findings that while access to opioid-dependency medication (ODM) increased in Massachusetts from 2010 to 2016 through greater numbers of ODM prescribers, opioid-related deaths rose even faster. Clearly, increasing the number of available ODM prescribers is only 1 of many factors that must be addressed to solve the opioid epidemic. We agree with Desai et al that despite the benefits of ODM among those receiving it, rates of opioid-related deaths are not likely to decrease if the incidence and prevalence of heroin use and other opioids (eg, fentanyl and even stronger synthetic opioids) continue to rise. Further, we note that prescribers are usually limited in the number of patients to whom they can offer ODM, so an increase in prescribers does not necessarily translate into a sharp increase in the number of patients receiving ODM. Moreover, only a minority of patients with opioid use disorder seek treatment because of stigma, beliefs that they do not need treatment, or structural barriers/accessibility to seek treatment after being treated for an opioid overdose.2 Of those who do, many drop out.3

    更新日期:2017-09-13
  • Association of Panic Disorder, Generalized Anxiety Disorder, and Benzodiazepine Treatment During Pregnancy With Risk of Adverse Birth Outcomes
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-13
    Kimberly Ann Yonkers, Kathryn Gilstad-Hayden, Ariadna Forray, Heather S. Lipkind
    更新日期:2017-09-13
  • National Trends in Suicide Attempts Among Adults in the United States
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-13
    Mark Olfson, Carlos Blanco, Melanie Wall, Shang-Min Liu, Tulshi D. Saha, Roger P. Pickering, Bridget F. Grant
    更新日期:2017-09-13
  • Suicide and Attempted Suicide in the United States During the 21st Century
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-13
    Eric D. Caine
    更新日期:2017-09-13
  • Correction of Misspelled Author Name
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-06

    In the Original Investigation titled “Developmental Trajectories of Impaired Community Functioning in Schizophrenia,” published in the January 2016 issue of JAMA Psychiatry,1 the surname of one of the authors was misspelled in the byline, Author Affiliations, and Author Contributions. The third author’s name was given as “Ori Kapara, BA,” but should have appeared as “Ori Kapra, BA.” This article was corrected online.

    更新日期:2017-09-07
  • Recent Changes in Health Insurance Coverage and Access to Care by Mental Health Status, 2012-2015
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-06
    Elizabeth Sherrill, Gilbert Gonzales
    更新日期:2017-09-07
  • Prevention of Anxiety Disorders Across the Lifespan
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-06
    Jennifer L. Hudson

    Anxiety disorders are the most common mental disorders across the lifespan and exact a massive disease burden.1 Anxiety disorders typically onset in childhood and predict a range of later mental health problems, such as depression, suicide, and substance abuse. Despite this, anxiety disorders are frequently underrecognized and overlooked as serious mental health problems. There are a number of factors that influence the limited attention anxiety disorders receive, both in terms of clinical practice and public health policy. The reduced focus is likely in part because of poor mental health literacy. There is a common misconception that anxiety disorders are reserved for the “worried well” and represent a personality flaw rather than a disorder. In addition, anxiety itself is a normal emotion, perhaps leading to misunderstanding surrounding the difference between normal and pathological fear and anxiety. The transient nature of some fears in early childhood may also lead to a misconception that the disorder will remit with time or maturation. For most individuals, anxiety disorders are relatively stable, long-term, and disabling and need to be taken seriously.

    更新日期:2017-09-07
  • Association of White Matter Structure With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-06
    Yuta Aoki, Yuliya N. Yoncheva, Bosi Chen, Tanmay Nath, Dillon Sharp, Mariana Lazar, Pablo Velasco, Michael P. Milham, Adriana Di Martino
    更新日期:2017-09-07
  • Effectiveness of Psychological and/or Educational Interventions in the Prevention of AnxietyA Systematic Review, Meta-analysis, and Meta-regression
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-06
    Patricia Moreno-Peral, Sonia Conejo-Cerón, Maria Rubio-Valera, Anna Fernández, Desirée Navas-Campaña, Alberto Rodríguez-Morejón, Emma Motrico, Alina Rigabert, Juan de Dios Luna, Carlos Martín-Pérez, Antonina Rodríguez-Bayón, María Isabel Ballesta-Rodríguez, Juan Vicente Luciano, Juan Ángel Bellón
    更新日期:2017-09-07
  • Heterogeneity Within and Between Autism Spectrum Disorder and Attention-Deficit/Hyperactivity DisorderChallenge or Opportunity?
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-06
    Stephanie H. Ameis

    Autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) are common neurodevelopmental disorders (NDDs), categorized separately in the DSM-5 and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10). Yet, there are significant clinical and neurobiological similarities among children with either ASD or ADHD. Considerable clinical and neurobiological heterogeneity within disorders is also present. The etiology of either ASD or ADHD remains unclear, although perturbation in large-scale neural connectivity has been implicated across disorders based on the association of genes that regulate neural migration and synaptic development with both disorders1 and case-control neuroimaging studies that demonstrated altered structural and functional connectivity across several neural networks in either disorder, compared with typically developing controls (TDCs). Although neuroscience research has provided important clues regarding neurodevelopmental alterations present in ASD and ADHD, findings that are inconsistent and nonspecific to either NDD limit the opportunities for clinical translation.

    更新日期:2017-09-07
  • JAMA Psychiatry
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-01

    Mission Statement: JAMA Psychiatry strives to publish original, state-of-the-art studies and commentaries of general interest to clinicians, scholars, and research scientists in psychiatry, mental health, behavioral science, and allied fields. The journal seeks to inform and to educate its readers as well as to stimulate debate and further exploration into the nature, causes, treatment, and public health importance of mental illness. The JAMA Network is a consortium of peer-reviewed print and online medical publications that includes JAMA®, JAMA Psychiatry, and other specialty journals. JAMA Psychiatry does not hold itself responsible for statements made by any contributor. All articles published, including opinion articles, represent the views of the authors and do not reflect the policy of the Journal, the American Medical Association, or the institution with which the author is affiliated, unless otherwise indicated.

    更新日期:2017-09-07
  • Errors in Abstract and Discussion
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-01

    In the Original Investigation titled “Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial,”1 published online July 12, 2017, there were errors in the abstract and discussion. In the Results section of the abstract, the bracketed number in “clonidine participants (22 [66.1%])” should be “61.1%” and the parenthetical numbers in “tramadol ER (71 [9.4%])” should be “(7 [19.4%]). In the second paragraph of the discussion section, the schedule number for tramadol ER should be IV. This article was corrected online.

    更新日期:2017-09-07
  • Ketamine for the Treatment of Depression
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-01
    Samad E. J. Golzari, Ata Mahmoodpoor

    To the Editor There is now convincing evidence that ketamine has properties to provide prompt antidepressant effects, especially in patients with resistant mood and anxiety disorders.1 Eventually, ketamine will be included in our daily practice. However, in addition to the concerns addressed by Sanacora et al,1 there are a few further complications to be taken into consideration by any practitioner.

    更新日期:2017-09-07
  • Ketamine for the Treatment of Depression—Reply
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-01
    Gerard Sanacora

    In Reply Rasmussen has correctly pointed out that the 0.5-mg/kg dose of racemic ketamine hydrochloride used in most published reports to date was not arrived at through extensive preclinical studies or strong experimental therapeutic rationale. In fact, the 0.5-mg/kg dose provided over a 40-minute intravenous infusion implemented in the original Berman et al1 study was adopted from a previous dosing strategy devised by Krystal et al2 as a means of assessing the acute psychotomimetic, perceptual, and cognitive effects of ketamine as a potential model of psychosis. The 0.5-mg/kg infusion over 40 minutes was chosen specifically because it resulted in clearly observable psychoactive effects but still allowed the patients to remain lucid enough to complete a battery of cognitive assessments, not because of any special belief about the optimal antidepressant dosing. We referred to this as the “standard dose” in the consensus statement3 solely because it was used in most published reports. Because this was the only dose with replicated findings across several clinical laboratories, it was the only dose that we felt comfortable evaluating at the present time. We did not mean to imply that this is the optimal or correct dose to be used for the treatment of mood disorders.

    更新日期:2017-09-07
  • Ketamine for the Treatment of Depression
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-01
    Keith G. Rasmussen

    To the Editor In their presentation of guidelines for the use of ketamine in mood disorders, Sanacora et al1 rightly state that ketamine is not standard treatment in psychiatry but then inexplicably refer to 0.5 mg/kg intravenously over 40 minutes as the “standard” dose. How can there be a standard dose for a nonstandard treatment? A brief review of the history of this dosing method is instructive. The first to use this dosing format for depression was Berman et al,2 who did not provide any rationale. They did cite Krystal et al,3 who used 0.5 mg/kg intravenously over 40 minutes for studies of ketamine in normal volunteers. In turn, that group cited, as a basis for this dosage and infusion rate, the classic studies of Domino et al4 and Corssen and Domino.5 However, those investigators infused ketamine over a few seconds to 1 minute. Thus, it would seem that the now familiar 0.5 mg/kg over 40 minutes is arbitrary, without any pharmacodynamic or pharmacokinetic rationale.

    更新日期:2017-09-07
  • Ketamine for the Treatment of Depression
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-01
    Christoph Kraus, Rupert Lanzenberger, Siegfried Kasper

    To the Editor We congratulate Sanacora et al1 for the publication of their consensus statement in JAMA Psychiatry. The growing amount of literature on this topic has generated interest among patients and physicians, which called for such an important document as the basis for decision-making societies, health care professionals, and regulatory authorities. Until official approval of depression as an indication, off-label uses by medical experts assuming legal, scientific, and medical hazards will increase. On the other hand, ketamine clinics or ketamine wellness centers already offer ketamine as outpatient treatment with unscientific and dangerous methods. To overcome the lack of regulation, consensus statements and their dissemination are of utmost importance.

    更新日期:2017-09-07
  • Assessment of Insulin Resistance Among Drug-Naive Patients With First-Episode Schizophrenia in the Context of Hormonal Stress Axis Activation
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-01
    Johann Steiner, Maximus Berger, Paul C. Guest, Henrik Dobrowolny, Sabine Westphal, Kolja Schiltz, Zoltán Sarnyai
    更新日期:2017-09-07
  • Cost Sharing and Mental Health CareA Cautionary Tale From the Netherlands
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-01
    Benjamin G. Druss

    Since health insurance first began covering mental health services in the mid-20th century, there have been debates about how best to balance comprehensiveness and affordability of mental health care benefits. In the United States, concerns about potential overuse initially led insurers to impose higher restrictions for mental health care than for other types of health care benefits. Over time, advocacy coupled with research demonstrating that these restrictions could be lifted without significant cost increases helped pave the way for broader mental health care coverage.1 During the past decade, federal legislation has placed mental health within the mainstream of health insurance, establishing it as an essential health benefit and ensuring that it covers a range of services comparable to those for other types of medical and surgical care.2

    更新日期:2017-09-07
  • Risk of Suicide Attempt Among Soldiers in Army Units With a History of Suicide Attempts
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-01
    Robert J. Ursano, Ronald C. Kessler, James A. Naifeh, Holly Herberman Mash, Carol S. Fullerton, Paul D. Bliese, Alan M. Zaslavsky, Tsz Hin Hinz Ng, Pablo A. Aliaga, Gary H. Wynn, Hieu M. Dinh, James E. McCarroll, Nancy A. Sampson, Tzu-Cheg Kao, Michael Schoenbaum, Steven G. Heeringa, Murray B. Stein
    更新日期:2017-09-07
  • Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating DisorderA Randomized Clinical Trial
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-01
    James I. Hudson, Susan L. McElroy, M. Celeste Ferreira-Cornwell, Jana Radewonuk, Maria Gasior
    更新日期:2017-09-07
  • Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use DisorderA Randomized Clinical Trial
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-01
    Sharon L. Walsh, Sandra D. Comer, Michelle R. Lofwall, Bradley Vince, Naama Levy-Cooperman, Debra Kelsh, Marion A. Coe, Jermaine D. Jones, Paul A. Nuzzo, Fredrik Tiberg, Behshad Sheldon, Sonnie Kim
    更新日期:2017-09-07
  • Efficacy of Tramadol Extended-Release for Opioid WithdrawalA Randomized Clinical Trial
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-01
    Kelly E. Dunn, D. Andrew Tompkins, George E. Bigelow, Eric C. Strain
    更新日期:2017-09-07
  • Association of Cost Sharing With Mental Health Care Use, Involuntary Commitment, and Acute Care
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-01
    Bastian Ravesteijn, Eli B. Schachar, Aartjan T. F. Beekman, Richard T. J. M. Janssen, Patrick P. T. Jeurissen
    更新日期:2017-09-07
  • Suicidal Behaviors Within Army UnitsContagion and Implications for Public Health Interventions
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-01
    Charles W. Hoge, Christopher G. Ivany, Amy B. Adler

    Between 2005 and 2009, during the peak war years in Iraq and Afghanistan, the US Army and US Marine Corps, the 2 services with the largest concentration of ground combat forces, experienced a significant increase in suicides. For the first time in decades, suicide rates surpassed civilian levels, and they have remained elevated since. This change precipitated considerable research by several teams to understand the causal factors,1 including the more than $65 million Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS), a population-based epidemiological study to identify “actionable recommendations to reduce Army suicides.”2 However, these extensive efforts reached somewhat contradictory conclusions concerning key risk factors, such as the association of deployment with suicide.1 The Army STARRS effort was the most prolific but generated the harshest criticism for its core scientific assumptions, methods, conclusions, and lack of actionable relevance.3- 5 To date, none of these studies have been able to definitively answer the overarching question of why suicide rates rose so sharply in Army and Marine personnel but not in Air Force and Navy personnel.1

    更新日期:2017-09-07
  • Clinical Care Across CulturesWhat Helps, What Hinders, What to Do
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-01
    Margarita Alegría, Kiara Alvarez, Irene Falgas-Bague

    Today’s clinicians must develop therapeutic alliances with patients with diverse customs, values, and experiences. This can be challenging, as clinicians must make decisions quickly, opening the door to attributional errors and unconfirmed assumptions about patients. In one study,1 white therapists were more likely than Chinese therapists to describe Chinese patients as having depression with interpersonal skill deficits, while Chinese therapists judged white patients as demonstrating more severe psychopathology than did white therapists.1 Problems stemming from the power imbalance between majority group clinicians and minority group patients are exacerbated when the patient is poor, nonwhite, or does not speak English well. Research shows that those who are powerful (typically clinicians) are prone to making hasty judgments, often applying stereotypes to the behavior of others.2 Because of time constraints and unconscious biases, clinicians may not spend sufficient time in “perspective taking” to understand the patient’s circumstances and may see themselves as more objective than they are.

    更新日期:2017-09-07
  • A Mitochondrial Etiology of Neuropsychiatric Disorders
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-01
    Douglas C. Wallace

    Enormous resources have been invested in the analysis of neuropsychiatric disorders using powerful genomics techniques, including genome-wide association studies (GWAS), whole-exome sequencing (WES), and whole-genome sequencing, to search for nuclear DNA (nDNA) gene variants associated with these disorders. Yet, no coherent pathophysiological etiology for psychiatric disorders has emerged. For example, after analysis of thousands of autism cases by GWAS and WES, numerous copy number variants and loss-of-function mutations have been identified, but no single variant accounts for a significant proportion of cases. Moreover, the genes that have been found to harbor loss-of-function mutations in patients with autism overlap with those associated with congenital heart disease and metabolic disorders.1 What do “brain” diseases have to do with congenital heart disease and metabolic disorders?

    更新日期:2017-09-07
  • Highlights
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-09-01

    Different manuals have been developed for evidence-based psychotherapies of mood and anxiety disorders. Barlow and colleagues studied a unified protocol for the transdiagnostic treatment in a randomized equivalence trial of 233 adult patients with various anxiety disorders. Reduction in symptom severity with the unified protocol was statistically equivalent to reductions with single-disorder protocols after 16 to 21 weeks of treatment and at the 6-month follow-up. In an Editorial, Roy-Byrne discusses the importance of the study for the dissemination of psychotherapy for anxiety disorders.

    更新日期:2017-09-07
  • Association Between Psychotic Experiences and Subsequent Suicidal Thoughts and BehaviorsA Cross-National Analysis From the World Health Organization World Mental Health Surveys
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-30
    Evelyn J. Bromet, Matthew K. Nock, Sukanta Saha, Carmen C. W. Lim, Sergio Aguilar-Gaxiola, Ali Al-Hamzawi, Jordi Alonso, Guilherme Borges, Ronny Bruffaerts, Louisa Degenhardt, Giovanni de Girolamo, Peter de Jonge, Silvia Florescu, Oye Gureje, Josep M. Haro, Yanling He, Chiyi Hu, Elie G. Karam, Viviane Kovess-Masfety, Sing Lee, Jean-Pierre Lepine, Zeina Mneimneh, Fernando Navarro-Mateu, Akin Ojagbemi, José Posada-Villa, Nancy A. Sampson, Kate M. Scott, Juan C. Stagnaro, Maria C. Viana, Miguel Xavier, Ronald C. Kessler, John J. McGrath
    更新日期:2017-08-30
  • Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and AdolescentsA Systematic Review and Meta-analysis
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-30
    Cosima Locher, Helen Koechlin, Sean R. Zion, Christoph Werner, Daniel S. Pine, Irving Kirsch, Ronald C. Kessler, Joe Kossowsky
    更新日期:2017-08-30
  • Effectiveness and Safety of Antidepressants for Children and AdolescentsImplications for Clinical Practice
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-30
    Sally Nicola Merry, Sarah Elisabeth Hetrick, Karolina Stasiak

    It is now well understood that disorders of anxiety and depression in children and adolescents are common, debilitating, and largely undetected and untreated.1 The mainstays of treatment include psychological therapy, predominantly cognitive behavioral therapy, and medication, usually antidepressants, which, despite their name, are also used for anxiety disorders and obsessive-compulsive disorder.2 In this issue of JAMA Psychiatry, Locher et al3 examine the evidence for selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine inhibitors (SNRIs) for children and adolescents with anxiety disorders, depressive disorders, obsessive-compulsive disorder, and posttraumatic stress disorder. To date, most reviews and meta-analyses have been focused on one or other disorder. Having the information gathered together in one review is helpful, particularly as there is a high rate of comorbidity between these disorders. Based on 36 studies with 6778 participants, the authors found modest effects sizes (Hedges g) from medication, ranging from 0.56 (95% CI, 0.40-0.72) for anxiety disorders through 0.39 (95% CI, 0.25-0.54) for obsessive-compulsive disorder to 0.20 (95% CI, 0.13-0.27) for depressive disorders. There was only 1 study showing no effect in posttraumatic stress disorder. Overall, the effect size was small (g = 0.32; 95% CI, 0.25-0.40).

    更新日期:2017-08-30
  • Error on X-axes in Figure 2
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-23

    In the Article titled “Changes in US Lifetime Heroin Use and Heroin Use Disorder: Prevalence From the 2001-2002 to 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions,”1 published online March 29, 2017, on the x-axes in Figure 2, the years for the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) III should be 2012-2013.

    更新日期:2017-08-23
  • Association Between Mitochondrial DNA Haplogroup Variation and Autism Spectrum Disorders
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-23
    Dimitra Chalkia, Larry N. Singh, Jeremy Leipzig, Maria Lvova, Olga Derbeneva, Anita Lakatos, Dexter Hadley, Hakon Hakonarson, Douglas C. Wallace
    更新日期:2017-08-23
  • Association of Lithium in Drinking Water With the Incidence of Dementia
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-23
    Lars Vedel Kessing, Thomas Alexander Gerds, Nikoline Nygård Knudsen, Lisbeth Flindt Jørgensen, Søren Munch Kristiansen, Denitza Voutchkova, Vibeke Ernstsen, Jörg Schullehner, Birgitte Hansen, Per Kragh Andersen, Annette Kjær Ersbøll
    更新日期:2017-08-23
  • Addiction Potential of Cigarettes With Reduced Nicotine Content in Populations With Psychiatric Disorders and Other Vulnerabilities to Tobacco Addiction
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-23
    Stephen T. Higgins, Sarah H. Heil, Stacey C. Sigmon, Jennifer W. Tidey, Diann E. Gaalema, John R. Hughes, Maxine L. Stitzer, Hanna Durand, Janice Y. Bunn, Jeff S. Priest, Christopher A. Arger, Mollie E. Miller, Cecilia L. Bergeria, Danielle R. Davis, Joanna M. Streck, Derek D. Reed, Joan M. Skelly, Lauren Tursi
    更新日期:2017-08-23
  • Could Lithium in Drinking Water Reduce the Incidence of Dementia?
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-23
    John J. McGrath, Michael Berk

    Now more than ever, the research community should be concentrating on finding ways to reduce the incidence of dementia. The population is aging, and the number of individuals affected by dementia remains a major public health challenge. The reality is that we have no effective treatments for dementia. In the absence of treatments to cure the disorder (or even reduce the associated burden by delaying onset or reducing disability), the prevention of dementia must be a priority research topic. Modifiable risk factors are associated with dementia1 (eg, diabetes and attendant behavioral risks, such as diet and physical activity); these risk factors are important but complex targets for intervention. However, as with many neurologic and psychiatric disorders, we have a scant appreciation of the environmental risk factors that contribute to dementia risk. There is an urgent need to generate new candidate risk factors for dementia. In contrast to genetics, for which there are now cost-efficient, high-throughput screening methods that can generate genetic candidates, epidemiology relies on a mix of creative researchers and access to suitable databases that contain the variables of interest. Epidemiologists are envious of our colleagues in genetics, in which the search space for risk variants is more tractable and bounded.

    更新日期:2017-08-23
  • The Benefits of Purposeful Life Engagement on Later-Life Physical Function
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-16
    Carol D. Ryff

    Although psychological disorders, such as depression and anxiety, have long been studied as factors that contribute to poorer health (broadly defined) over time, it is only in the last few years that psychological strengths have emerged as having possible protective influences on health. One such strength is purpose in life, which was first formulated from the life experiences of Victor Frankl, who spent 3 years in a Nazi concentration camp.1 He saw purpose in life as having life-saving features and went on to develop a form of psychotherapy based on it. What does purpose in life mean? It is about reflective activities in which individuals perceive their existence to be meaningful and to include goals for which they live. Sometimes, this takes proactive efforts. In 1989, I developed a structured, self-report scale to measure purpose in life,2 along with 5 other dimensions of psychological well-being. Since then, more than 500 publications have grown up around this model of well-being. Components of it have been linked to a host of other domains (aging, work and family life, personality, health, and interventions).3 However, without question, the greatest amount of new science that has taken well-being in the direction of health has involved purpose in life. Frankl, a psychiatrist by training, saw it was essential for sustaining life, particularly under conditions of adversity. A growing body of evidence suggests he was probably right.

    更新日期:2017-08-16
  • Polygenic Scores for Major Depressive Disorder and Risk of Alcohol Dependence
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-16
    Allan M. Andersen, Robert H. Pietrzak, Henry R. Kranzler, Li Ma, Hang Zhou, Xiaoming Liu, John Kramer, Samuel Kuperman, Howard J. Edenberg, John I. Nurnberger, John P. Rice, Jay A. Tischfield, Alison Goate, Tatiana M. Foroud, Jacquelyn L. Meyers, Bernice Porjesz, Danielle M. Dick, Victor Hesselbrock, Eric Boerwinkle, Steven M. Southwick, John H. Krystal, Myrna M. Weissman, Douglas F. Levinson, James B. Potash, Joel Gelernter, Shizhong Han
    更新日期:2017-08-16
  • Association Between Purpose in Life and Objective Measures of Physical Function in Older Adults
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-16
    Eric S. Kim, Ichiro Kawachi, Ying Chen, Laura D. Kubzansky
    更新日期:2017-08-16
  • JAMA Psychiatry
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-01

    Mission Statement: JAMA Psychiatry strives to publish original, state-of-the-art studies and commentaries of general interest to clinicians, scholars, and research scientists in psychiatry, mental health, behavioral science, and allied fields. The journal seeks to inform and to educate its readers as well as to stimulate debate and further exploration into the nature, causes, treatment, and public health importance of mental illness. The JAMA Network is a consortium of peer-reviewed print and online medical publications that includes JAMA®, JAMA Psychiatry, and other specialty journals. JAMA Psychiatry does not hold itself responsible for statements made by any contributor. All articles published, including opinion articles, represent the views of the authors and do not reflect the policy of the Journal, the American Medical Association, or the institution with which the author is affiliated, unless otherwise indicated.

    更新日期:2017-08-11
  • Assessing Depression Among New Fathers—Reply
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-01
    Lisa Underwood, Susan M. B. Morton, Karen E. Waldie

    In Reply Laurent and Bianchi are concerned that our recent study1 on paternal antenatal and postnatal depression symptoms did not control for prepregnancy depression. Mother and partner participants were recruited to the study during pregnancy.2 As such, it was not possible to carry out standardized assessment of prepregnancy depression symptoms. However, participants were asked to report whether they had ever been diagnosed as having depression by a physician. This variable was included in the models for paternal antenatal depression symptoms (PADS) and paternal postnatal depression symptoms (PPDS). Prepregnancy depression was significantly associated with PPDS (increased odd ratio, of 2.84; 95% CI, 1.69-4.78) and all other odds ratios were controlled for this variable.

    更新日期:2017-08-11
  • Assessing Depression Among New Fathers
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-01
    Eric Laurent, Renzo Bianchi

    To the Editor Underwood and colleagues1 published an article related to depression in new fathers. In their study, the authors assessed paternal antenatal depression symptoms (PADS) and paternal postnatal depression symptoms (PPDS). From their analyses, the authors drew conclusions about the first practical action to take, which would consist of “increasing awareness among fathers about increased risks.”1 We noticed several methodological problems in the study that directly bear on the authors’ conclusions.

    更新日期:2017-08-11
  • Reviews and Meta-analyses of Psychotherapy Efficacy for Borderline Personality Disorder—Reply
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-01
    Ioana Alina Cristea, Corrado Barbui, Pim Cuijpers

    In Reply We thank Faltinsen and colleagues for their judicious comments on our meta-analysis1 and will hereby address each point. The authors underscore the lack of a registered protocol, which we fully acknowledge as a limitation. However, as meta-analyses deal with secondary observational data, the potential pernicious influence of investigator biases might be lessened. The authors maintain selective reporting in systematic reviews is widespread, but cite evidence pertaining primarily to inadequate harm reporting in primary trials included in systematic reviews, rather than in reviews themselves. For these, the evidence for selective outcome reporting and its association with outcomes is mixed.2 Nevertheless, for full transparency, we made all extracted data publicly available (https://figshare.com/articles/Data_for_Cristea_et_al_2017_JAMA_Psychiatry/4892111).

    更新日期:2017-08-11
  • Internet-Based Self-Help Interventions for Depression in Routine Care—Reply
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-01
    Eirini Karyotaki, Heleen Riper, Pim Cuijpers

    In Reply We thank Ebert and Baumeister for their insightful response. We agree that the results of our study should be considered with caution, as we also indicated in our article.1 First, the authors highlight that they would have appreciated a more detailed discussion about the interpretation of the clinical significance of our findings, especially regarding the small effect. While we acknowledge that we need to be cautious when interpreting the clinical relevance, we consider self-guided interventions that have a number needed to treat of 8 to be potentially helpful for populations that are not willing to seek professional help, for use during watchful waiting in primary care, or in low- and middle-income countries with no or only a limited infrastructure for mental health services.1 We note here that as reported by Muñoz and colleagues,2 “Massive open online interventions have the potential to increase the reach, scalability, and affordability of psychological interventions.” Even a small effect can have a huge impact when it is applied in large populations. Therefore, self-guided internet-based cognitive behavioral therapy can have a large impact on mental health, despite the small effect sizes. We also point to the fact that an effect size of g = 0.27 (95% CI, 0.17-0.37) may be small, but not very different from other treatments. For example, the effect size of antidepressant medication vs placebo is also only g = 0.31 (95% CI, 0.27-0.35).3

    更新日期:2017-08-11
  • Reviews and Meta-analyses of Psychotherapy Efficacy for Borderline Personality Disorder
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-01
    Erlend Glasø Faltinsen, Mickey Kongerslev, Ole Jakob Storebø

    To the Editor We thank Cristea and colleagues1 for their compelling review on psychotherapy for borderline personality disorder (BPD). The authors found that psychotherapies, especially dialectical behavior therapy and psychodynamic approaches, are effective for borderline symptoms and related problems, although the effects were small and inflated by risk of bias. Here, we point out some unrecognized limitations of their study.

    更新日期:2017-08-11
  • Internet-Based Self-help Interventions for Depression in Routine Care
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-01
    David Daniel Ebert, Harald Baumeister

    To the Editor The outstanding individual participant data meta-analysis by Karyotaki and colleagues1 highlights the efficacy of self-guided internet-based interventions for depressive symptoms, thereby making the case for the use of individual participant data meta-analysis as a gold standard for evidence-based mental health care. However, the discussion would have benefited from a more differentiated point of view regarding the clinical significance of their findings.

    更新日期:2017-08-11
  • Network Meta-analysis in Mental Health Treatment Research—Reply
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-01
    Andre Russowsky Brunoni, Wagner Gattaz, Anna Chaimani

    In Reply Network meta-analyses (NMAs) represent a new paradigm in mental health treatment research that have been seldom used and can be reliable and useful.1 Thus, we thank Roth et al and Feifel for their letters commenting on our NMA2 and bringing up some issues for discussion. It should be underscored that our NMA results regarding the efficacy and acceptability of high-frequency, low-frequency, and θ-burst stimulation and bilateral repetitive transcranial magnetic stimulation (rTMS)—which represent 95% of the included studies—are in line with previous pairwise meta-analyses findings.3- 5

    更新日期:2017-08-11
  • Network Meta-analysis in Mental Health Research
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-01
    Yiftach Roth, Gaby Simon Pell, Abraham Zangen

    To the Editor The network meta-analysis of various repetitive transcranial magnetic stimulation (rTMS) modalities in major depressive disorder by Brunoni et al1 is fairly comprehensive, given the limited criteria for article selection used in this analysis. Such an approach could enhance understanding of rTMS efficacy and tolerability; however, if not implemented with great care, it can also lead to distorted conclusions.

    更新日期:2017-08-11
  • Network Meta-analysis in Mental Health Research
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-01
    David Feifel

    To the Editor We applaud the attempt by Brunoni et al1 to shed light on the comparative efficacy and safety of various repetitive transcranial magnetic stimulation (rTMS) strategies for treating depressive disorders by performing a network meta-analysis (NMA) on the extant published literature. The unique ability of NMA to leverage indirect evidence for a treatment’s efficacy from a network of clinical trials is a potential advantage; however, as pointed out by Mills et al,2 it can also produce distorted results when the analysis is applied incautiously to treatments (nodes) that are not well connected in the network, ie, those only studied against 1 or 2 comparators.

    更新日期:2017-08-11
  • Suicide Rates and the Declining Psychiatric Hospital Bed Capacity in the United States
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-01
    Robert D. Gibbons, Kwan Hur, J. John Mann
    更新日期:2017-08-11
  • A Risk Calculator for Bipolar Spectrum Disorder in Youth at Familial Risk
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-01
    Esther Mesman, Manon H. J. Hillegers

    A positive family history for bipolar disorder (BD) is presently the strongest predictor for BD. Over the last 2 decades, several longitudinal studies among children of patients with BD (bipolar offspring) identified converging evidence for early BD manifestations and associated parental and environmental risk factors.1 Risk for BD is elevated in bipolar offspring, but affected families want to know an individual risk estimate. Moreover, clinicians and policy makers want to know how to identify those youth at ultra high risk because this information may affect treatment and monitoring strategies. In this issue of JAMA Psychiatry, Hafeman and colleagues2 present a risk calculator for bipolar spectrum disorder (BPSD) in youth at familial risk for BD. Their work is an important step forward in the BD research field and potentially for clinical practice. Risk calculators are novel in psychiatry3 but are well-known instruments in general medicine (eg, the Framingham Risk Score is a widely used tool to assess risk for cardiovascular diseases). By entering specific risk variables, risk calculators may guide clinicians to weigh individual risk for disease and aid clinical decision making (eg, starting early intervention and frequent monitoring). The study by Hafeman and colleagues2 is the first to date to investigate the use of a risk calculator in youth at familial risk for BD.

    更新日期:2017-08-11
  • Efficacy of Stimulants Beyond Treatment of Core Symptoms of Attention-Deficit/Hyperactivity Disorder
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-01
    Luis Augusto Rohde

    Although the use of stimulants continues to increase in all age groups in the United States,1 an important debate has emerged in the last 2 years about how effective stimulants are for treating attention-deficit/hyperactivity disorder (ADHD). For some investigators, the main message in the literature is clear: the quality of evidence from randomized clinical trials on the efficacy of stimulants is poor.2 For others, the problem is in the meta-analysis from which these conclusions were taken.3

    更新日期:2017-08-11
  • Use of Instrumental Variables Methods in Examining Psychiatric Readmissions
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-01
    Anthony T. Lo Sasso

    In this issue of JAMA Psychiatry, Slade et al1 take on difficult questions about the effects of electroconvulsive therapy (ECT) on patient health outcomes. Specifically, the authors try to measure the causal effect of ECT on inpatient hospital readmission for psychiatric reasons among patients with severe psychiatric conditions. The challenge with this question is that patients who receive ECT are likely different from patients who don’t receive ECT over a range of factors that may also affect readmission risks. For example, ECT might be appropriate for patients with greater demonstrated compliance with treatments or patients with particular kinds of insurance. Such patients would likely have higher or lower readmission rates, even in the absence of ECT. To address concerns about biases, the authors propose instrumental variable (IV) statistical analyses.

    更新日期:2017-08-11
  • Assessment of a Person-Level Risk Calculator to Predict New-Onset Bipolar Spectrum Disorder in Youth at Familial Risk
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-01
    Danella M. Hafeman, John Merranko, Tina R. Goldstein, David Axelson, Benjamin I. Goldstein, Kelly Monk, Mary Beth Hickey, Dara Sakolsky, Rasim Diler, Satish Iyengar, David A. Brent, David J. Kupfer, Michael W. Kattan, Boris Birmaher
    更新日期:2017-08-11
  • Inflammation in the Neurocircuitry of Obsessive-Compulsive Disorder
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-01
    Sophia Attwells, Elaine Setiawan, Alan A. Wilson, Pablo M. Rusjan, Romina Mizrahi, Laura Miler, Cynthia Xu, Margaret Anne Richter, Alan Kahn, Stephen J. Kish, Sylvain Houle, Lakshmi Ravindran, Jeffrey H. Meyer
    更新日期:2017-08-11
  • Role of Positive Parenting in the Association Between Neighborhood Social Disadvantage and Brain Development Across Adolescence
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-01
    Sarah Whittle, Nandita Vijayakumar, Julian G. Simmons, Meg Dennison, Orli Schwartz, Christos Pantelis, Lisa Sheeber, Michelle L. Byrne, Nicholas B. Allen
    更新日期:2017-08-11
  • Association Between Medication Use and Performance on Higher Education Entrance Tests in Individuals With Attention-Deficit/Hyperactivity Disorder
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-01
    Yi Lu, Arvid Sjölander, Martin Cederlöf, Brian M. D’Onofrio, Catarina Almqvist, Henrik Larsson, Paul Lichtenstein
    更新日期:2017-08-11
  • Placebo Response and Practice Effects in Schizophrenia Cognition Trials
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-08-01
    Richard S. E. Keefe, Vicki G. Davis, Philip D. Harvey, Alexandra S. Atkins, George M. Haig, Owen Hagino, Stephen Marder, Dana C. Hilt, Daniel Umbricht
    更新日期:2017-08-11
Some contents have been Reproduced with permission of the American Chemical Society.
Some contents have been Reproduced by permission of The Royal Society of Chemistry.
所有期刊列表A-Z